Company Research Report: Xylo Bio

Company Overview

• Name: Xylo Bio (formerly Psylo)

• Mission: Xylo Bio aims to transform lives with targeted neurotherapeutics, developing next-generation therapeutics designed to rewire neural circuits and restore brain function in patients with neurological and psychiatric disorders. Their mission is focused on delivering breakthrough therapies that address critical unmet needs and improve patient lives.

• Founded: 2021, originally under the name Psylo. The company rebranded to Xylo Bio in 2025.

• Founder(s): No information is available.

• Key People:

• Joshua Ismin, CEO

• Dr. Samuel Banister, Chief Scientific Officer

• Elaine Stead, PhD, Board Member, Partner at Main Sequence Ventures

• Margarita Chavez, JD, Board Member, Venture Partner at Wellington Life Sciences Partners

• Headquarters: No information is available.

• Number of Employees: No information is available.

• Revenue: No information is available.

• What the Company is Known For: Xylo Bio is known for pioneering neuroplastogens, which are small molecule therapies designed to rewire neural circuits and restore brain function, particularly in psychiatric and neurological disorders.

Products

• XYL-1001:

• Description: A new chemical entity designed to rewire neural circuits without hallucinatory effects. It aims to treat neurological disorders with greater efficacy and safety. Clinical trials are planned for mid-2026.

• Key Features:

• Non-hallucinogenic

• Designed for greater safety and efficacy

• Plans for scale-up manufacturing

• PSYLO-100X (developed prior to rebranding):

• Description: A non-hallucinogenic neuroplastogen designed to treat depression and other mental disorders.

• Key Features:

• Non-hallucinogenic

• Partially selective 5-HT2A agonist

• Promotes neuroplasticity

• Demonstrates antidepressant effects, possibly improving cognition

• Safer, enabling potential in-home administration without clinical supervision

Recent Developments

• Rebranding: The company rebranded from Psylo to Xylo Bio in January 2025 to reflect its growth and sharpened focus on neuroscience and neuroplastogens.

• Funding:

• In June 2024, Psylo announced a successful first close of $8 million Series Seed financing to advance neuroplastogens like PSYLO-100X.

• In October 2024, the company received a $3 million grant to accelerate the development of neuroplastogens for substance use disorder treatment.

• Board Appointments and Strategic Changes:

• The appointment of Elaine Stead and Margarita Chavez to the board in 2025 to strengthen leadership and strategic vision.

• Research Partnerships:

• Collaborative efforts include a strategic partnership with Daiichi Sankyo to develop non-hallucinogenic psychiatric therapies.

• Product Development:

• Launch and scale-up of lead candidate XYL-1001, with a planned first-in-human clinical trial by mid-2026.

• Ongoing development and promising therapeutic potential for PSYLO-100X in addressing mental health disorders.

Conclusion

Xylo Bio, formerly known as Psylo, is focused on pioneering next-generation neurotherapeutic solutions through the development of neuroplastogens. The company is advancing its pipeline with significant financial backing and strategic board appointments, positioning itself for impactful contributions to the treatment of psychiatric and neurological disorders.